Psychiatric comorbidity in a sample of opiate-dependent patients treated with sublingual buprenorphine in a therapeutic community regime

González‐Sáiz, Francisco; Lozano, Óscar; Esteban, Juana Martín; Acedos, Izaskun Bilbao; Gómez, Rosario Ballesta; Ortega, Josefa Gutiérrez

doi:10.1016/s2173-5050(11)70013-9

Cited by 5 publications

(3 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…OUD is associated with a host of adverse consequences, including infectious disease, overdoses, and premature death, as well as significant economic costs (Birnbaum et al, 2011; Clausen, Waal, Thoresen, & Gossop, 2009; Hser, Hoffman, Grella, & Anglin, 2001; Jones, Mack, & Paulozzi, 2013). Psychiatric comorbidities, particularly mood, anxiety, and personality disorders, are also highly prevalent among individuals with OUD (Strain, 2002), with prevalence of psychiatric disorders in this group nearly fourfold that of the general population (Callaly, Trauer, Munro, & Whelan, 2001; González-Saiz et al, 2011; Kessler, Chiu, Demler, Merikangas, & Walters, 2005; Kidorf et al, 2004). Concurrent opioid dependence and psychiatric distress also likely confer additive vulnerabilities.…”

mentioning

confidence: 99%

Interim buprenorphine treatment during delays to comprehensive treatment: Changes in psychiatric symptoms.

Streck¹,

Ochalek²,

Badger³

et al. 2018

Experimental and Clinical Psychopharmacology

View full text Add to dashboard Cite

Prevalence of depression, anxiety, and mood disorders among individuals with opioid use disorder far exceeds that of the general population. While psychiatric symptoms often improve upon entry into opioid treatment, this has typically been seen with treatments involving psychosocial counseling. In this secondary analysis, we examined changes in psychiatric symptoms during a randomized clinical trial evaluating an interim buprenorphine treatment without counseling among individuals awaiting entry into comprehensive treatment. Waitlisted adults with opioid use disorder ( = 50) were randomized to one of two 12-week conditions: interim buprenorphine treatment (IBT; = 25) consisting of buprenorphine maintenance using a computerized medication dispenser, with bimonthly clinic visits and technology-assisted monitoring, or waitlist control (WLC; = 25), wherein participants remained on the waitlist of their local clinic. All participants completed assessments of psychiatric symptoms at intake and Study Weeks 4, 8, and 12. We examined changes on the Beck Anxiety Inventory (BAI), Beck Depression Inventory-II (BDI-II), Brief Symptom Inventory (BSI), and Psychiatric subscale of the Addiction Severity Index (ASI). Significant group-by-time interactions were observed for all measures of psychiatric severity examined: BAI ( < .05), BDI-II ( < .01), 5 BSI subscales (s < .05), and the ASI Psychiatric subscale ( < .05). On all measures, IBT participants reported significantly reduced psychiatric severity at the 4-, 8-, and 12-week assessments relative to baseline. In contrast, there were no significant changes in psychiatric symptoms among WLC participants. IBT without counseling may improve psychiatric distress among waitlisted individuals with opioid use disorder. (PsycINFO Database Record

show abstract

mentioning

confidence: 99%

Interim buprenorphine treatment during delays to comprehensive treatment: Changes in psychiatric symptoms.

Streck¹,

Ochalek²,

Badger³

et al. 2018

Experimental and Clinical Psychopharmacology

View full text Add to dashboard Cite

show abstract

“…Although prevalence in European adults is low, OUD is associated with high morbidity and mortality rates. Comorbidities include blood-borne infectious diseases -especially human immunodeficiency virus and hepatitis C virus (HCV) [3][4][5] -as well as psychiatric disorders such as depression, anxiety, and dissocial personality disorder [6]. Harmful effects related to use of drugs such as risk of overdose, unemployment, crime, homelessness, or social exclusion, should also be considered [2].…”

Section: Introductionmentioning

confidence: 99%

Perception of a New Prolonged-Release Buprenorphine Formulation in Patients with Opioid Use Disorder: The PREDEPO Study

et al. 2021

View full text Add to dashboard Cite

Aim: The aim of the study was to assess the acceptance of patients with opioid use disorder (OUD) to switching their opioid dependence treatment (ODT) for a prolonged-release buprenorphine (PRB) injection according to their prior ODT (buprenorphine/naloxone [B/N] or methadone). Methods: This was an observational, retrospective/cross-sectional, multicentre study of adult patients diagnosed with OUD on ODT. Data collected from diaries were analysed to know their interest and opinion on PRB. Questions with fixed response options were included, and several Likert scales were used. Results: A total of 98 patients were enrolled (B/N: 50.0%, methadone: 50.0%). The mean age was 46.9 ± 8.43 years and 79.6% were males. PRB was similarly perceived by both groups in most variables analysed, receiving a mean score of 7.2/10 (B/N: 7.4, methadone: 7.0; p = 0.520), and approximately 65% of patients said they were willing to switch to PRB (B/N: 63.3%, methadone: 65.3%; p = 0.833). Of these, a higher percentage in the B/N group considered that switching would be easy/very easy (B/N: 90.3%, methadone: 46.9%; p < 0.001) and that they would start PRB when available (B/N: 64.5%, methadone: 34.3%; p = 0.005). More than 90% would prefer the monthly injection (B/N: 93.6%, methadone: 100%; p = 0.514). One-third of patients in both groups were unsure/would not switch their ODT to PRB (B/N: 36.7%, methadone: 34.7%; p = 0.833). The main reason was administration by injection. Conclusion: Two-thirds of patients would switch their treatment for PRB, and most patients on B/N considered that switching would be easy. PRB could be a suitable alternative for OUD management.

show abstract

“…El TCO está asociado con una alta tasa de morbimortalidad, siendo las enfermedades infecciosas y los trastornos psiquiátricos las comorbilidades más frecuentes (González-Saiz et al, 2011;Mateu, Astasls y Torrens, 2005;Roncero et al, 2016). Muchos consumidores de opioides a largo plazo en Europa practican el policonsumo, por lo que el TCO también se asocia a problemas relacionados con el consumo de drogas como la sobredosis, delincuencia, desempleo, la exclusión y desventajas sociales, entre otros (Observatorio Europeo de las Drogas y las Toxicomanías, 2020).…”

unclassified

Satisfacción y experiencia de pacientes en tratamiento con sustitutivos opioides en España. Estudio PREDEPO

Pastor¹,

Muñoz²,

Oraá³

et al. 2021

Adicciones

View full text Add to dashboard Cite

Psychiatric comorbidity in a sample of opiate-dependent patients treated with sublingual buprenorphine in a therapeutic community regime

Cited by 5 publications

References 18 publications

Interim buprenorphine treatment during delays to comprehensive treatment: Changes in psychiatric symptoms.

Interim buprenorphine treatment during delays to comprehensive treatment: Changes in psychiatric symptoms.

Perception of a New Prolonged-Release Buprenorphine Formulation in Patients with Opioid Use Disorder: The PREDEPO Study

Satisfacción y experiencia de pacientes en tratamiento con sustitutivos opioides en España. Estudio PREDEPO

Contact Info

Product

Resources

About